INT56160

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1993
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 15
Disease Relevance 11.39
Pain Relevance 5.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
vestibular ganglion 2
Ifx (Mus musculus)
Pain Link Frequency Relevance Heat
Adalimumab 1112 100.00 Very High Very High Very High
Infliximab 520 100.00 Very High Very High Very High
Etanercept 113 100.00 Very High Very High Very High
Arthritis 75 99.70 Very High Very High Very High
rheumatoid arthritis 164 96.40 Very High Very High Very High
Multiple sclerosis 17 94.08 High High
antagonist 75 91.56 High High
Crohn's disease 28 88.08 High High
Inflammation 79 87.56 High High
Neuritis 3 87.20 High High
Disease Link Frequency Relevance Heat
Cold Sores 570 100.00 Very High Very High Very High
Demyelinating Disease 30 99.84 Very High Very High Very High
Seronegative Spondarthritis 64 99.70 Very High Very High Very High
Ganglion Cysts 6 99.34 Very High Very High Very High
Disease 616 98.32 Very High Very High Very High
Colitis 77 97.92 Very High Very High Very High
Heart Rate Under Development 22 97.36 Very High Very High Very High
Systemic Lupus Erythematosus 51 97.20 Very High Very High Very High
Sprains And Strains 110 96.72 Very High Very High Very High
Rheumatoid Arthritis 165 96.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Notably, we did not observe a significant increase in H3K4me2 enrichment associated with the ICP0 promoter region of HSV-1 after the application of our reactivation stimulus through 4 h post-treatment.
HSV-1 Binding (associated) of associated with cold sores
1) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973973 Disease Relevance 0.36 Pain Relevance 0
The increased H3K4me2 enrichment indicates that the ICP4 promoter of HSV-1 undergoes chromatin remodeling to a more permissive chromatin profile, rapidly following TCIE.
HSV-1 Binding (undergoes) of associated with cold sores
2) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973973 Disease Relevance 0.38 Pain Relevance 0
HSV-1 has a genome of 152?
HSV-1 Binding (genome) of associated with cold sores
3) Confidence 0.36 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2938438 Disease Relevance 0.91 Pain Relevance 0.04
TLR3 seems to be the dominant TLR involved in recognition of HSV-1, and patients with dominant-negative TLR3 mutations were recently found to be highly susceptible to herpes simplex encephalitis (HSE) [312].
HSV-1 Binding (recognition) of associated with meningitis and cold sores
4) Confidence 0.35 Published 2010 Journal The Open Virology Journal Section Body Doc Link PMC2936037 Disease Relevance 0.55 Pain Relevance 0.10
Histopathological and immunohistochemical examinations showed degeneration of the vestibular ganglion cells in 4 of the 5 mice, while HSV-1 antigens were recognized in 2 of them.
HSV-1 Binding (recognized) of in vestibular ganglion associated with ganglion cysts and cold sores
5) Confidence 0.35 Published 1994 Journal Nippon Jibiinkoka Gakkai Kaiho Section Abstract Doc Link 8064504 Disease Relevance 0.82 Pain Relevance 0.08
The HSV-1 antigens were recognized exclusively in Scarpa's ganglion of the vestibular nerve in 2 of 4 mice in which signs of vestibular involvement were manifested.
HSV-1 Binding (recognized) of in Scarpa's ganglion associated with ganglion cysts and cold sores
6) Confidence 0.35 Published 1993 Journal Acta Otolaryngol Suppl Section Abstract Doc Link 8385869 Disease Relevance 0.62 Pain Relevance 0.16
 ; however, membrane-bound TNF is not, or less, recognized by ETC 28, whereas IFX and ADA also bind to this uncleaved form.
IFX Binding (bind) of associated with infliximab, adalimumab and etanercept
7) Confidence 0.30 Published 2008 Journal International Journal of Medical Sciences Section Body Doc Link PMC2452978 Disease Relevance 0.84 Pain Relevance 0.83
Treatment with ETC (fig 3 E,F) and with IFX (fig. 3 G,H) and the absence of the receptor-1 for TNF-?
IFX Binding (Treatment) of associated with infliximab and etanercept
8) Confidence 0.28 Published 2008 Journal International Journal of Medical Sciences Section Body Doc Link PMC2452978 Disease Relevance 0.90 Pain Relevance 0.41
Both patients had been treated earlier with IFX and were negative for ANA before beginning IFX therapy.
IFX Binding (treated) of associated with infliximab
9) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 1.31 Pain Relevance 0.58
Both IFX and etanercept have been linked to demyelinating disease.
IFX Binding (linked) of associated with infliximab, demyelinating disease and etanercept
10) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 1.11 Pain Relevance 0.66
This patient, who was refractory to conventional therapy, including G-CSF, and was intolerant to IFX, showed a complete clinical and endoscopic remission after 22 weeks of ADA treatment.
IFX Binding (intolerant) of associated with infliximab and adalimumab
11) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.71 Pain Relevance 0.60
Results of each of these studies, as well as data from other uncontrolled reports have shown that ADA can be effective in inducing and maintaining clinical response and remission in CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to IFX.
IFX Binding (intolerant) of associated with infliximab, adalimumab and disease
12) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.66 Pain Relevance 0.20
In CD, ADA has received both FDA and EMEA approval with the following indications: 1) for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active CD who have had an inadequate response to conventional therapy, and 2) for reducing the signs and symptoms and inducing clinical remission in these patients if they have also lost response or are intolerant to IFX.
IFX Binding (intolerant) of associated with infliximab, adalimumab and disease
13) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.80 Pain Relevance 0.67
To appraise the efficacy, safety, and cost-effectiveness of early therapy with IFX, we conducted a systematic review of the literature and performed a meta-analysis of the RA bone erosion score (vdH Sharp Score) and RA functional disability score (HAQ)

Methods

IFX Binding (therapy) of associated with infliximab and rheumatoid arthritis
14) Confidence 0.20 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 1.05 Pain Relevance 0.57
Patients with PsA who had prior IFX or ETN therapy or both achieved clinically meaningful ACR50 and mPsARC response rates of 41.7%, and 71.2%, respectively.
IFX Binding (therapy) of associated with infliximab, etanercept and arthritis
15) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.36 Pain Relevance 0.85

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox